Furthermore, a decrease in tumor cell proliferation and angiogenesis and increased apoptosis have been described in in vitro and in vivo uLMS models after treatment with vandetanib, a VEGFR2/epidermal growth factor receptor (EGFR) inhibitor [35]. This evidence concerns the gene EGFR and neoplasm.